What's behind those billion-dollar biotech deals? Often, a whole lot of hype
UniQure Building

It was a good day for UniQure, a Dutch biotech company at work on gene therapies for rare diseases. A big pharma company had just made a billion-dollar investment in its future. Or so the headlines blared. Eighteen months and two CEOs later, UniQure is laying off about a quarter of its staff, abandoning some of…